Krystal Biotech, Inc. $KRYS Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.8% in the 1st quarter, Holdings Channel reports. The institutional investor owned 162,070 shares of the company’s stock after selling 3,004 shares during the period. Principal Financial Group Inc.’s holdings in Krystal Biotech were worth $41,866,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Soleus Capital Management L.P. increased its holdings in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares during the last quarter. Norges Bank acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $70,159,000. William Blair Investment Management LLC lifted its position in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after buying an additional 227,038 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Krystal Biotech by 2,078.9% in the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after buying an additional 209,369 shares during the last quarter. Finally, UBS Group AG lifted its position in shares of Krystal Biotech by 970.8% in the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock worth $39,347,000 after buying an additional 177,922 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 26,642 shares of company stock worth $8,243,923. Corporate insiders own 13.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. HC Wainwright lifted their target price on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Wolfe Research initiated coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating for the company. Finally, Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $360.67.

Krystal Biotech Stock Up 3.8%

KRYS stock opened at $354.86 on Friday. The stock has a market cap of $10.46 billion, a PE ratio of 47.44 and a beta of 0.50. The firm’s 50-day simple moving average is $331.38 and its 200 day simple moving average is $289.47. Krystal Biotech, Inc. has a fifty-two week low of $130.50 and a fifty-two week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Equities analysts forecast that Krystal Biotech, Inc. will post 7.41 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.